Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upc…
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2- metastatic breast cancer – – Interim data from Phase 1…
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
Designation indicates entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP) NEW HAVEN, Conn. and NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that the U.K. Innovativ…
Arvinas Announces Changes to its Board of Directors
NEW HAVEN, Conn., June 15, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Timothy Shannon, M.D., current Chairperso…
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
– 42% of patients with AR ligand binding domain (LBD) mutations achieved PSA 50 ; in patients with AR L702H mutations, 3 of 5 achieved PSA 50 – – ARV-766 was well-tolerated, and activity in a heavily pre-treated patient population supports its potentia…
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcomi…
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
NEW HAVEN, Conn. and NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology…
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
–Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests potential clinical benefit in a heavily pretreated patient…
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
NEW HAVEN, Conn., May 03, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and…
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial
NEW HAVEN, Conn. and SAN FRANCISCO , May 2, 2023 /PRNewswire/ — Arvinas, Inc. (Nasdaq: ARVN) and Quantum Leap Healthcare Collaborative™ today announced that Arvinas’ vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader bein…
